AVTX - Avalo Therapeutics, Inc. Stock Price, Fair Value and News

$8.91-0.17 (-1.87%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

AVTX Price Action

Last 7 days

-3.5%

Last 30 days

-18.3%

Last 90 days

-8.3%

Trailing 12 Months

-25.7%

AVTX RSI Chart

AVTX Valuation

Market Cap

92.6M

Price/Earnings (Trailing)

-11.64

Price/Sales (Trailing)

54.51

EV/EBITDA

-1.37

Price/Free Cashflow

-2.52

AVTX Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

AVTX Fundamentals

AVTX Revenue

Revenue (TTM)

1.7M

Rev. Growth (Yr)

5.51%

Rev. Growth (Qtr)

-56.39%

AVTX Earnings

Earnings (TTM)

-8.0M

Earnings Growth (Yr)

540.65%

Earnings Growth (Qtr)

-76.6%

AVTX Profitability

EBT Margin

-468.92%

Return on Equity

-37.76%

Return on Assets

-8.08%

Free Cashflow Yield

-39.71%

AVTX Investor Care

Shares Dilution (1Y)

1196.66%

Diluted EPS (TTM)

29.41

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	0	0	1.7M	0
2023	14.0M	10.0M	6.0M	1.9M
2022	6.1M	3.8M	17.4M	18.1M
2021	4.4M	6.4M	6.7M	5.4M
2020	6.9M	6.9M	5.8M	6.7M
2019	7.0M	6.9M	6.8M	6.8M
2018	32.2M	36.5M	15.6M	7.0M
2017	1.5M	10.3M	19.1M	27.8M
2016	0	0	0	1.2M

Get all data in R, Python etc through our Historical Stock Data APIs

About Avalo Therapeutics, Inc.

Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation. The company's drug candidates include AVTX-002, a fully human anti-LIGHT monoclonal antibody, which is under Phase II clinical trial for the treatment of non-eosinophilic asthma, as well as Crohn's disease; Phase III clinical trial for the treatment of COVID-19 acute respiratory distress syndrome; and AVTX-008, a fully human B and T Lymphocyte Attenuator (BTLA) agonist fusion protein. It also develops AVTX-803, a L-fucose monosaccharide therapy for treatment of Leukocyte Adhesion Deficiency Type II. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.

CEO	Dr. Garry A. Neil M.D.
WEBSITE	avalotx.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	20

Avalo Therapeutics, Inc. Frequently Asked Questions

What is the ticker symbol for Avalo Therapeutics, Inc.? What does AVTX stand for in stocks?

AVTX is the stock ticker symbol of Avalo Therapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Avalo Therapeutics, Inc. (AVTX)?

As of Fri Dec 20 2024, market cap of Avalo Therapeutics, Inc. is 92.61 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of AVTX stock?

You can check AVTX's fair value in chart for subscribers.

Is Avalo Therapeutics, Inc. a good stock to buy?

The fair value guage provides a quick view whether AVTX is over valued or under valued. Whether Avalo Therapeutics, Inc. is cheap or expensive depends on the assumptions which impact Avalo Therapeutics, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for AVTX.

What is Avalo Therapeutics, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Dec 20 2024, AVTX's PE ratio (Price to Earnings) is -11.64 and Price to Sales (PS) ratio is 54.51. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. AVTX PE ratio will change depending on the future growth rate expectations of investors.